Pfizer Venture Investments

Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development, Strategy, and Innovation division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of the pharmaceutical industry.

With a $50 million annual budget for private investments, PVI may invest up to $10 million per round in selected companies in any stage of development, with a strong focus on growth-stage opportunities. Other investments, including fund investing, spinout opportunities, and Private Investment in Public Equity (PIPEs) will also be considered as appropriate.

Investment Strategy

We consider investments in a broad array of health care-related areas, including therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, health care IT, and other technologies impacting drug discovery and development. We will consider companies at all stages of development, including start-ups, spinouts, and consortia investments. While primarily U.S.-focused, international investments may represent up to 20% of the portfolio. We have the ability to lead or join a syndicate of investors and will seek board representation as appropriate.

Our Team Is Looking Forward to Working With You

• Barbara Dalton, PhD, Vice President
• Elaine Jones, PhD, Executive Director
• Bill Burkoth, Director
• Jennifer Friel Goldstein, Director

Pictured: Bill Burkoth, Elaine Jones, Jennifer Friel Goldstein, and Barbara Dalton

• Take a look at our investments
• Submit your business plan

• Submit an inquiry